PMID- 25972325
OWN - NLM
STAT- MEDLINE
DCOM- 20150728
LR  - 20190221
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 143
IP  - 6
DP  - 2015 Jun
TI  - p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma 
      From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
PG  - 830-8
LID - 10.1309/AJCPOATJ9L4GCGDA [doi]
AB  - OBJECTIVES: It can be difficult to differentiate diffuse malignant peritoneal 
      mesothelioma (DMPM) from reactive mesothelial hyperplasia (RMH) or peritoneal 
      dissemination of gynecologic malignancies, such as epithelial ovarian cancer 
      (EOC), which cause a large amount of ascites. Detection of the homozygous 
      deletion of p16/CDKN2A (p16) by fluorescence in situ hybridization (FISH) is an 
      effective adjunct in the diagnosis of malignant pleural mesothelioma. The aim of 
      this study was to investigate the ability of the p16 FISH assay to differentiate 
      DMPM from RMH and EOC. METHODS: p16 FISH was performed in 28 DMPMs (successful in 
      19), 30 RMHs, and 40 EOC cases. The cutoff values of p16 FISH were more than 10% 
      for homozygous deletion and more than 40% for heterozygous deletion. RESULTS: 
      According to the above criteria, nine (47.4%) of 19 successful DMPM cases were 
      homozygous deletion positive, and three (15.8%) of 19 were heterozygous deletion 
      positive, whereas all RMH cases were negative for the p16 deletion. In all four 
      major histologic subtypes of EOC, neither p16 homozygous nor heterozygous 
      deletions were detected. To differentiate DMPM from RMH or EOC, the sensitivity 
      of the p16 homozygous deletion was 32% (9/28), and the specificity was 100%. 
      CONCLUSIONS: Our study suggests that p16 FISH analysis is useful in 
      differentiating DMPM from RMH and EOC when homozygous deletion is detected.
CI  - Copyright(c) by the American Society for Clinical Pathology.
FAU - Ito, Tomohiro
AU  - Ito T
AD  - From the Department of Pathology and Department of Obstetrics and Gynecology, 
      Fukuoka University School of Medicine and Hospital, Fukuoka, Japan;
FAU - Hamasaki, Makoto
AU  - Hamasaki M
AD  - From the Department of Pathology and.
FAU - Matsumoto, Shinji
AU  - Matsumoto S
AD  - From the Department of Pathology and.
FAU - Hiroshima, Kenzo
AU  - Hiroshima K
AD  - Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, 
      Yachiyo, Japan;
FAU - Tsujimura, Tohru
AU  - Tsujimura T
AD  - Department of Pathology, Hyogo College of Medicine, Hyogo, Japan;
FAU - Kawai, Toshiaki
AU  - Kawai T
AD  - Department of Pathology and Laboratory Medicine, National Defense Medical 
      College, Tokorozawa, Japan;
FAU - Shimao, Yoshiya
AU  - Shimao Y
AD  - Department of Pathology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan;
FAU - Marutsuka, Kousuke
AU  - Marutsuka K
AD  - Department of Pathology, Miyazaki University School of Medicine, Miyazaki, Japan; 
      and.
FAU - Moriguchi, Sayaka
AU  - Moriguchi S
AD  - Department of Pathology, Miyazaki University School of Medicine, Miyazaki, Japan; 
      and.
FAU - Maruyama, Riruke
AU  - Maruyama R
AD  - Laboratory of Surgical Pathology, Shimane University School of Medicine, Izumo, 
      Japan.
FAU - Miyamoto, Shingo
AU  - Miyamoto S
AD  - Department of Obstetrics and Gynecology, Fukuoka University School of Medicine 
      and Hospital, Fukuoka, Japan;
FAU - Nabeshima, Kazuki
AU  - Nabeshima K
AD  - From the Department of Pathology and kaznabes@fukuoka-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Ovarian Epithelial
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics
MH  - *Diagnosis, Differential
MH  - Female
MH  - *Genes, p16
MH  - Humans
MH  - Hyperplasia/diagnosis/genetics
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Mesothelioma/*diagnosis/genetics
MH  - Middle Aged
MH  - Neoplasms, Glandular and Epithelial/*diagnosis/genetics
MH  - Ovarian Neoplasms/*diagnosis/genetics
MH  - Peritoneal Neoplasms/*diagnosis/genetics
MH  - Precancerous Conditions/diagnosis/genetics
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - 9p21
OT  - Diffuse malignant peritoneal mesothelioma
OT  - Epithelial ovarian cancer
OT  - Fluorescence in situ hybridization
OT  - Reactive mesothelial hyperplasia
OT  - p16
EDAT- 2015/05/15 06:00
MHDA- 2015/07/29 06:00
CRDT- 2015/05/15 06:00
PHST- 2015/05/15 06:00 [entrez]
PHST- 2015/05/15 06:00 [pubmed]
PHST- 2015/07/29 06:00 [medline]
AID - 143/6/830 [pii]
AID - 10.1309/AJCPOATJ9L4GCGDA [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2015 Jun;143(6):830-8. doi: 10.1309/AJCPOATJ9L4GCGDA.